Glivec 400 mg contains Imatinib Mesylate, a first-generation BCR-ABL tyrosine kinase inhibitor that revolutionized the treatment of chronic myeloid leukemia. It is administered orally and is widely used in hematology and oncology for targeted cancer therapy.

🔬 Mechanism of Action

Imatinib selectively inhibits specific tyrosine kinases, including:

• BCR-ABL (associated with Philadelphia chromosome–positive leukemia)
• KIT (CD117)
• PDGFR (Platelet-Derived Growth Factor Receptor)

By blocking these abnormal signaling pathways, it prevents cancer cell proliferation and induces apoptosis (cell death).

💊 Indications

Glivec 400 mg is indicated for:

• Chronic Myeloid Leukemia (CML) (all phases)
• Philadelphia chromosome–positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST) (KIT-positive)
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
• Dermatofibrosarcoma Protuberans (DFSP)
• Other approved indications as per oncology guidelines

📌 Key Features of Glivec 400 mg

• Strength: 400 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Tyrosine Kinase Inhibitor (TKI)
• Administration: Taken orally once daily with food and water
• Monitoring: Regular complete blood counts and liver function tests required

⚕️ Benefits of Imatinib Mesylate

• Targeted therapy with high specificity
• Improves long-term survival in CML
• Oral administration for patient convenience
• Effective in multiple kinase-driven cancers

⚠️ Precautions

• May cause fluid retention, edema, nausea, and fatigue
• Risk of liver toxicity
• Myelosuppression may occur
• Drug interactions possible
• Use strictly under oncologist supervision

• Glivec 400 mg (Imatinib Mesylate Tablets) is a landmark targeted therapy in oncology, offering effective and long-term disease control for patients with CML, GIST, and other kinase-driven cancers when administered under specialist care.